HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Norihisa Shigemura Hikaru Matsuda Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shigemura, N. Articles by Matsuda, H. Search for Related Content PubMed PubMed Citation Articles by Shigemura, N. Articles by Matsuda, H. Related Collections Lung - cancer

Ann Thorac Surg 2004;77:1016-1021
© 2004 The Society of Thoracic Surgeons

---

Original article: general thoracic

Pleural perfusion thermo-chemotherapy under VATS: a new less invasive modality for advanced lung cancer with pleural spread

^a Division of General Thoracic Surgery, Takarazuka Municipal Hospital, Hyogo, Japan
^b Department of Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

Accepted for publication August 19, 2003.

^* Address reprint requests to Dr Shigemura, Department of Surgery, Osaka University Graduate School of Medicine, E-1, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
e-mail: n-shige{at}blue.ocn.ne.jp

BACKGROUND: We conducted a trial of a new less invasive, locoregional modality for lung cancer with pleural spread. This study was planned to investigate the feasibility, safety, and pharmacokinetics of pleural perfusion thermochemotherapy (PPTC) under video-assisted thoracoscopic surgery (VATS) and its modified method with a short perfusion time for preventing heat damage to the lung during the procedure.

METHODS: Seventeen patients, 59 to 79 years old, underwent surgical resection of the primary lesions and PPTC under VATS without thoracotomy. All had pleural spread with malignant effusion due to lung cancer proven before the treatment. PPTC consists of irrigating the pleural space with 42°C saline solution containing cisplatin (200 mg/m²) using a devised circuit. The time for perfusion was two hours in 10 patients (group L), and one hour in 7 patients (group S).

RESULTS: All patients successfully completed this treatment with acceptable toxicities. The pharmacokinetic analysis showed that high platinum levels for the regional pleural exposure, which was 20- to 40-fold greater than those for the plasma in both groups. These values were equivalent between the groups, although the levels for the plasma were higher in group L than in group S. Postoperative lung damage was seen in 4 patients with no serious conditions in group L, and none in group S. The median survival for the L and S groups was 17 and 19 months, respectively.

CONCLUSIONS: This less invasive modality seems to offer a safe, feasible, and pharmacokinetically advantageous procedure to have excellent local control for lung cancer with pleural spread.

This article has been cited by other articles:

				M. Lucchi and A. Mussi Reply to Heyman and Van Schil Eur. J. Cardiothorac. Surg., September 1, 2008; 34(3): 708 - 708. [Full Text] [PDF]

				E. de Bree, S. van Ruth, C. E. Schotborgh, P. Baas, and F. A. N. Zoetmulder Limited Cardiotoxicity after Extensive Thoracic Surgery and Intraoperative Hyperthermic Intrathoracic Chemotherapy with Doxorubicin and Cisplatin Ann. Surg. Oncol., October 1, 2007; 14(10): 3019 - 3026. [Abstract] [Full Text] [PDF]

				V. Patel and J. B. Shrager Which Patients with Stage III Non-Small Cell Lung Cancer Should Undergo Surgical Resection? Oncologist, May 1, 2005; 10(5): 335 - 344. [Abstract] [Full Text] [PDF]